logo
  

BioNTech Q1 Profit Surges; Backs FY22 COVID-19 Vaccine Revenue View - Quick Facts

BioNTech SE (BNTX), a German bio-tech firm, reported Monday that its first-quarter net profit surged to 3.70 billion euros from last year's 1.13 billion euros.

Earnings per share were 14.24 euros or $15.972, up from last year's 4.39 euros.

First -quarter revenues were 6.37 billion euros, up from 2.05 billion euros a year ago.

Looking ahead for fiscal 2022, the company continues to expect COVID-19 vaccine revenue of 13 billion euros to 17 billion euros.

The revenue estimate reflects expected revenues related to BioNTech's share of gross profit from COVID-19 vaccine sales in the collaboration partners' territories, from direct COVID-19 vaccine sales to customers in BioNTech's territory and expected revenues generated from products manufactured by BioNTech and sold to collaboration partners.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon has unveiled millions of deals worldwide that will be available during its upcoming Prime Day extravaganza. The 48-hour shopping event for Prime members kicks off July 12 at 3 a.m. EDT, offering deals of up to 79% off across various categories. These include electronics, devices, toys, beauty, fashion, and home, from top national brands and small businesses. Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores. The U.S. Food and Drug Administration has authorized state-licensed pharmacists to prescribe COVID-19 pill Paxlovid (nirmatrelvir and ritonavir) by drug major Pfizer Inc. to eligible patients, with certain limitations. The agency has revised the Emergency Use Authorization or EUA for Paxlovid for the authorization, which could improve access for some patients at high risk for severe covid-19.
Follow RTT